CRVO 14.30 CervoMed Inc.
| Range: | 5.85-26.38 | Vol Avg: | 84304 | Last Div: | 0 | Changes: | 0.25 |
| Beta: | 0 | Cap: | 0.12B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Fri May 23 2008 | Empoloyees: | 8 | ||
| CUSIP: | CIK: | 0001053691 | ISIN: | US15713L1098 | Country: | US | |
| CEO: | Dr. John J. Alam M.D. | Website: | https://www.cervomed.com | ||||
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of drug treatments for neurodegenerative diseases. It develops neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, and brain stroke recovery. The company is based in Boston, Massachusetts.
Stock Details
CRVO 55
Chardan Capital Markets Starts CervoMed (CRVO) at Buy
Danill Gataulin·Wed Sep 18 2024
Loop Capital Markets
CRVO 55
CervoMed initiated with a Buy at Chardan
Daniil Gataulin·Wed Sep 18 2024
Chardan Capital
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow